Skip to main content

Table 1 Comparison of demographics and clinical factors between General and Study Cohorts

From: Combined chemoradiotherapy showed improved outcome with early-stage HPV-positive oropharyngeal cancers

Variables, no. (%)

General Cohort (n = 727)

Study Cohort (n = 244)

p-value

p16-positive (n = 189)

p16-negative (n = 55)

p-value

Age, years (Mean ± SD)

60.1 ± 10.5

57.3 ± 9.4

< 0.01

56.4 ± 9.2

60.3 ± 9.5

< 0.01

Sex

  

0.53

  

0.21

 Male

569 (78.3)

186 (76.2)

 

148 (78.3)

38 (69.1)

 

 Female

158 (21.7)

58 (23.8)

 

41 (21.7)

17 (30.9)

 

Anatomical sitea

  

< 0.01

  

0.03

 Tonsil

314 (43.2)

190 (77.9)

 

153 (81.0)

37 (67.3)

 

 Base of tongue

311 (42.8)

48 (19.7)

 

33 (17.5)

15 (27.3)

 

 Other oropharynxb

98 (13.5)

5 (2.0)

 

2 (1.1)

3 (5.5)

 

Smoking historyc

  

0.22

  

< 0.01

 Never-smoker

137 (18.8)

54 (22.1)

 

49 (25.9)

5 (9.1)

 

 Ever-smoker

590 (81.2)

186 (76.2)

 

137 (72.5)

49 (89.1)

 

Primary treatment

  

0.37

  

0.22

 RT

430 (59.1)

136 (55.7)

 

101 (53.4)

35 (63.6)

 

 CRT

297 (40.9)

108 (44.3)

 

88 (46.6)

20 (36.4)

 

5-year survival

  

0.06

  

< 0.01

 Alive

451 (62.0)

168 (68.9)

 

142 (75.1)

26 (47.3)

 

 Died of disease

168 (23.1)

53 (21.7)

 

36 (19.0)

17 (30.9)

 

 Died of other cause

108 (14.9)

23 (9.4)

 

11 (5.8)

12 (21.8)

 
  1. Abbreviations: RT Radiotherapy, CRT Concurrent chemoradiotherapy
  2. aUnknown primary (n = 5)
  3. bIncludes: Soft palate (n = 48), Oropharyngeal wall (n = 32), Vallecula (n = 14), Uvula (n = 8), Anterior surface of epiglottis (n = 1)
  4. cUnknown smoking status (n = 4)